8-K: NeuroPace Appoints Experienced Medical Device Veteran Patrick Williams as New CFO, Rebecca Kuhn Transitions to Advisory Role

NeuroPace, Inc. announced a strategic leadership transition with the appointment of Patrick F. Williams as Chief Financial Officer, succeeding Rebecca Kuhn who will move into a Senior Strategic Advisor role.

Summary

• NeuroPace, Inc. has appointed Patrick F. Williams as its new Chief Financial Officer, effective June 20, 2025.
• Mr. Williams will also serve as the company's principal financial officer and principal accounting officer.
• Rebecca Kuhn, the outgoing CFO and Vice President, Finance and Administration, transitioned to the role of Senior Strategic Advisor-Finance, effective June 20, 2025.
• Ms. Kuhn will provide consulting services to NeuroPace from June 20, 2025, through June 19, 2026.
• In connection with her resignation, Ms. Kuhn will receive severance benefits including 12 months of base salary continuation and up to 18 months of COBRA premium reimbursement.
• Ms. Kuhn will also receive a one-time cash payment of $88,885, equivalent to her pro-rated 2025 bonus.
• Her outstanding equity awards will continue to vest during the consulting period, and vested awards remain exercisable.
• Patrick F. Williams brings over 25 years of financial and operational management experience with public medical device companies, including prior CFO roles at STAAR Surgical, Sientra, and ZELTIQ Aesthetics.
• Mr. Williams' base salary will be $500,000 per year, with an annual target bonus of 60% of his base salary.
• He will receive sign-on equity awards of 10,370 restricted stock units (RSUs) and 17,600 stock options, plus new hire equity awards of 41,480 RSUs and 70,350 stock options.
• These equity awards will vest 25% on the one-year anniversary of the grant date, with the remainder vesting quarterly over the subsequent three years.
• The Separation Agreement with Ms. Kuhn and the Offer Letter with Mr. Williams will be filed as exhibits to the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment regarding the strategic CFO transition, highlighting the extensive experience of the new appointee and a smooth handover process with the outgoing CFO remaining in an advisory role. This suggests stability and a focus on future growth, which is generally favorable.

Positives

• NeuroPace has secured an experienced financial leader, Patrick F. Williams, with over 25 years of experience in public medical device companies, including multiple CFO roles.
• Mr. Williams' background includes managing worldwide finance operations for companies like STAAR Surgical, which reported over $300 million in net sales in 2024, indicating experience with scaling and growth.
• The transition of the outgoing CFO, Rebecca Kuhn, to a Senior Strategic Advisor role ensures continuity and allows the company to retain her 25 years of institutional knowledge for a transitional period.
• Management expressed confidence that Mr. Williams' financial leadership will be a tremendous asset in expanding access to the RNS System and driving long-term value.
• The RNS System is highlighted as uniquely positioned to become the standard of care for drug-resistant epilepsy, with potential to benefit approximately 1.2 million U.S. patients.

Negatives

• The departure of a long-tenured CFO (25 years) like Rebecca Kuhn, despite a smooth transition, could represent a loss of deep institutional knowledge and relationships over the long term.

Risks

• Uncertainties related to market acceptance and adoption of NeuroPace's RNS System.
• Risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for NeuroPace's RNS System.
• Risks related to clinical development, including risks related to unfavorable or inconsistent clinical data from ongoing clinical studies.
• Other important factors detailed in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

NeuroPace anticipates continued growth and aims to expand access to its RNS System. The company believes the RNS System is uniquely positioned to become the standard of care for the approximately 1.2 million U.S. patients living with drug-resistant epilepsy, both in existing and anticipated future expanded indications. Management is committed to product and data development to drive better patient outcomes and support greater utilization of the RNS System.

Management Comments

• Joel Becker, President and CEO: "NeuroPace is pleased to have a financial leader of Patrick's caliber join the team at a time of such significant opportunity for our RNS System and critical point in our growth trajectory."
• Joel Becker, President and CEO: "He brings a strong track record of success helping medical device companies scale and grow, and his financial leadership will be a tremendous asset as we continue to expand access to the RNS System. His experience across commercial-stage and high-growth organizations will be valuable as we focus on driving long-term value."
• Joel Becker, President and CEO: "On behalf of the NeuroPace board and employees, I would like to acknowledge and thank Rebecca for her dedication to NeuroPace and for all that she has done for the Company and for our patients over her 25-year tenure."
• Patrick F. Williams, new CFO: "I am incredibly excited to join NeuroPace at such a pivotal time. The Company is just beginning to tap into a significant market opportunity, with the potential to bring life-changing benefits to the approximately 1.2 million U.S. patients living with drug resistant epilepsy."
• Patrick F. Williams, new CFO: "I believe the RNS System is uniquely positioned to become the standard of care in both our existing and anticipated future expanded indications, and I am energized by the Company's commitment to product and data development to drive better patient outcomes and support greater utilization."

Industry Context

This announcement occurs within the specialized medical device industry, particularly focusing on neurostimulation for epilepsy treatment. The appointment of Patrick F. Williams, with his extensive background in public medical device companies like STAAR Surgical (implantable lenses), Sientra (medical aesthetics), ZELTIQ Aesthetics (medical device acquisition), and NuVasive (spine medical device), signals NeuroPace's intent to leverage seasoned expertise to navigate growth and market expansion in a highly regulated and innovation-driven sector. His experience with companies that have achieved significant sales (e.g., STAAR Surgical's >$300M in 2024) suggests a focus on scaling commercial operations and financial management within the medical technology landscape.

Comparison to Industry Standards

• Patrick F. Williams' previous role as CFO at STAAR Surgical, a company that reported net sales of over $300 million in 2024, indicates his experience managing financial operations for a significant commercial-stage medical device company. This suggests NeuroPace is bringing in leadership with a track record at a scale that is substantial within the specialized medical device sector.
• His experience across multiple medical device companies (Sientra, ZELTIQ Aesthetics, NuVasive) demonstrates a broad understanding of financial and operational challenges and successes common in the industry, including growth, acquisitions, and product unit management.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO with a strong track record in the medical device industry may instill confidence in the company's financial management and strategic direction, potentially positively influencing investor sentiment.
• Employees: The smooth transition of the CFO role, with the outgoing CFO remaining in an advisory capacity, suggests stability in leadership and a commitment to continuity.
• Patients: The new CFO's stated excitement about expanding access to the RNS System and advancing NeuroPace's mission indicates a continued focus on patient benefits and market penetration for the company's core product.

Next Steps

• The Separation Agreement with Rebecca Kuhn and the Offer Letter with Patrick F. Williams will be filed as exhibits to NeuroPace's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• NeuroPace will continue to focus on expanding access to the RNS System and driving its utilization.
• The company plans to continue product and data development to support better patient outcomes and greater utilization of the RNS System.

Key Dates

Recommendation

Keywords

NeuroPace, CFO appointment, Chief Financial Officer, Rebecca Kuhn, Patrick F. Williams, medical device, epilepsy, RNS System, executive change, SEC filing, 8-K, corporate governance